Moderna

Public profile

Moderna, Inc. ( mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

📖 Wikipedia 📈 MRNA

▸✏️ Suggest a correction

Spot something wrong? Edit the fields — changes go live immediately and are logged for audit.

Wikipedia URLChanging the Wikipedia URL re-triggers full enrichment (bio + image auto-fill).Profile image URLBio (English)Bio (Hebrew)

📡 Recent posts· 0

No posts pulled in yet. Add where this person/organization posts below, and the platform starts pulling in new posts.

Where they post

No outlets set yet.

📊 FinancialMRNA · NASDAQ

$49.89

+0.25 · +0.50%

Prev close: $49.64

Mkt cap$20.2B

Open$49.83

High$51.75

Low$49.62

% from low0.54%

Loading chart…

▾ 📰 Recent news8 headlines · MRNA

Moderna (MRNA) Stock Looks Slightly Overvalued After Recent Rebound In Mixed Return Picture
Yahoo· 8h ago

Moderna stock overview Moderna (MRNA) has drawn fresh attention after recent trading left the stock around $49.64, with returns mixed over the past week and month but well ahead year to date compared with the past 3 y…
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
Yahoo· 13h ago

It's important to consider your comfort with risk before diving in.
How to Play PBLS Stock After the Parabilis IPO
Yahoo· 1d ago

Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.
3 Unpopular Stocks We Steer Clear Of
Yahoo· 2d ago

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as …
Parabilis sets a record with a $670M biotech IPO
Yahoo· 2d ago

The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.
Moderna, Inc. (MRNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
SeekingAlpha· 3d ago

Moderna, Inc. (MRNA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 3:20 PM EDTCompany ParticipantsJames Mock - Chief Financial...
Does Moderna Need to Start Making Money?
Yahoo· 3d ago

Moderna Is Losing Billions. Here's Why That Might Be Exactly the Right Strategy.
Reported Earlier, Moderna And University Of Oxford Receive UK MHRA Authorization To Begin Phase 1/2 Study Of mRNA Cancer Vaccine For Lynch Syndrome
Benzinga· 3d ago

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]The INTERCEPT-Lynch trial is part of a scientific collaboration between the University of Oxford and